Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: Current status and recent developments

David Reynoso, Jonathan Trent

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and is a paradigm of targeted therapy for solid tumors. Elucidation of the biology of GIST enabled use of imatinib, which revolutionized the prognosis of advanced GIST. Whereas surgical resection continues to be the standard of care for primary GIST, judicious and individualized use of adjuvant and neoadjuvant imatinib may enhance the potential for cure in select patients. RECENT FINDINGS: Prospective trials utilizing adjuvant and neoadjuvant imatinib have established the safety and efficacy of these modalities adjunct to surgical resection. Correlative tissue studies derived from these trials have examined gene expression patterns, metabolic and radiographic response, and apoptosis during the first few days of imatinib therapy. As appropriate use of adjuvant and neoadjuvant imatinib requires proper patient selection, development of a predictive nomogram, and advances in mutational analysis represent progress toward individualized care. SUMMARY: Imatinib is well tolerated and beneficial as adjuvant and neoadjuvant therapy, but its utility in these settings continues to be refined. The greatest benefit will derive from an individualized approach that considers multiple patient, drug, and tumor characteristics to assess risk and likelihood of benefit for each patient.

Original languageEnglish
Pages (from-to)330-335
Number of pages6
JournalCurrent Opinion in Oncology
Volume22
Issue number4
DOIs
StatePublished - Jul 1 2010
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Therapeutics
Neoplasms
Nomograms
Neoadjuvant Therapy
Standard of Care
Patient Selection
Gastrointestinal Tract
Imatinib Mesylate
Apoptosis
Safety
Gene Expression
Pharmaceutical Preparations

Keywords

  • adjuvant
  • GIST
  • imatinib
  • neoadjuvant

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor : Current status and recent developments. / Reynoso, David; Trent, Jonathan.

In: Current Opinion in Oncology, Vol. 22, No. 4, 01.07.2010, p. 330-335.

Research output: Contribution to journalArticle

@article{9173bf5436d64699ac0400f6c9210544,
title = "Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: Current status and recent developments",
abstract = "Lippincott Williams &Wilkins.",
keywords = "adjuvant, GIST, imatinib, neoadjuvant",
author = "David Reynoso and Jonathan Trent",
year = "2010",
month = "7",
day = "1",
doi = "10.1097/CCO.0b013e32833aaaad",
language = "English",
volume = "22",
pages = "330--335",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor

T2 - Current status and recent developments

AU - Reynoso, David

AU - Trent, Jonathan

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Lippincott Williams &Wilkins.

AB - Lippincott Williams &Wilkins.

KW - adjuvant

KW - GIST

KW - imatinib

KW - neoadjuvant

UR - http://www.scopus.com/inward/record.url?scp=77953960843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953960843&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32833aaaad

DO - 10.1097/CCO.0b013e32833aaaad

M3 - Article

C2 - 20520542

AN - SCOPUS:77953960843

VL - 22

SP - 330

EP - 335

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -